Julia Doulgere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julia Doulgere has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Benjamin Otto
Department of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publicationChristoph Wagener
Department of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication- Gerrit Wolters-Eisfeld
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication - Holger Rohde
Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf
1 shared publication Maher Nassour
Department of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publicationThomas Streichert
Department of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Clinical Chemistry, University Hospital Cologne, Cologne, Germany
1 shared publication
Latest Publications
- Open Access
Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case–control study
Objectives: To investigate whether the adherens junction protein vascular endothelial cadherin (VE-cadherin) is released during Shiga toxin 2 producing Escherichia coli (STEC) infection with haemolytic uraemic syndrome (HUS) and thus could be used to assist diagnosis. Design: Using data from the large 2011 STEC outbreak in northern Europe, we determined VE-cadherin plasma concentrations in 356 patients distributed over three patient cohorts: patients with STEC infection accompanied by HUS (STEC-HUS), STEC patients without HUS (STEC) and control patients with diarrhoea but without STEC infection. We then looked for associations between VE-cadherin concentrations and disease severity defined by changes in lactate dehydrogenase, haemoglobin, creatinine, platelet count, haptoglobin and neurological symptoms. Setting: This study was conducted at the University Medical Center Hamburg-Eppendorf, Germany. Participants: 79 STEC-HUS patients, 77 STEC patients and 200 control patients were enrolled in the study. Results: We analysed 864 specimens (207 STEC, 449 STEC-HUS and 208 controls) in total. At admission, VE-cadherin concentration tended to be lower in STEC-HUS patients compared to other patients. However, HUS patients later showed an increase in VE-cadherin concentrations with prolonged elevation beyond remission. This pattern clearly differs from that observed in non-HUS patients. Conclusions: VE-cadherin concentrations are elevated in STEC-HUS patients and might be a biomarker reflecting endothelial damage in patients with HUS.
Open AccessSoluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case–control study
Objectives: To investigate whether the adherens junction protein vascular endothelial cadherin (VE-cadherin) is released during Shiga toxin 2 producing Escherichia coli (STEC) infection with haemolytic uraemic syndrome (HUS) and thus could be used to assist diagnosis. Design: Using data from the large 2011 STEC outbreak in northern Europe, we determined VE-cadherin plasma concentrations in 356 patients distributed over three patient cohorts: patients with STEC infection accompanied by HUS (STEC-HUS), STEC patients without HUS (STEC) and control patients with diarrhoea but without STEC infection. We then looked for associations between VE-cadherin concentrations and disease severity defined by changes in lactate dehydrogenase, haemoglobin, creatinine, platelet count, haptoglobin and neurological symptoms. Setting: This study was conducted at the University Medical Center Hamburg-Eppendorf, Germany. Participants: 79 STEC-HUS patients, 77 STEC patients and 200 control patients were enrolled in the study. Results: We analysed 864 specimens (207 STEC, 449 STEC-HUS and 208 controls) in total. At admission, VE-cadherin concentration tended to be lower in STEC-HUS patients compared to other patients. However, HUS patients later showed an increase in VE-cadherin concentrations with prolonged elevation beyond remission. This pattern clearly differs from that observed in non-HUS patients. Conclusions: VE-cadherin concentrations are elevated in STEC-HUS patients and might be a biomarker reflecting endothelial damage in patients with HUS.